Previous 10 | Next 10 |
2023-09-03 09:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-09-03 03:45:00 ET Summary Shanghai GenFleet Technologies partners with Verastem in a deal worth up to $625.5 million for three preclinical small-molecule candidates for RAS pathway-driven cancers. Shanghai Kangpu Biopharmaceuticals raises $13.8 million in a B funding round to...
2023-08-28 16:10:44 ET Verastem ( NASDAQ: VSTM ) said it has entered into a collaboration deal with Chinese biotech GenFleet that allows it to license up to three drug candidates for commercialization outside of China. Under the deal, GenFleet will receive $11.5M for the first o...
Synergistic Collaboration Based on Strengths of Verastem Oncology’s Pipeline and Development Expertise and GenFleet Therapeutics’ Discovery Capabilities Exclusive Option for Verastem Oncology to License Up to Three Programs with Development and Commercialization Rights ...
2023-08-15 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-08-08 17:27:13 ET Verastem press release ( NASDAQ: VSTM ): Q2 Non-GAAP EPS of -$1.06 misses by $0.04 . Strengthened Balance Sheet, Including Receipt of Gross Proceeds of $97.8M from June 2023 Public Offering, Bringing Company Cash, Cash Equivalents, and Investment...
Presented Positive Results from Part A of RAMP 201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) at American Society of Clinical Oncology Meeting Established Design for RAMP 301 Phase 3 Confirmatory Trial of Avutometinib and Defactinib in Recurr...
2023-07-17 11:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-11 07:22:01 ET Verastem Oncology ( NASDAQ: VSTM ) COO and President Dan Paterson has been promoted to President and Chief Executive Officer role, effective August 1, 2023. Brian Stuglik will retire from the CEO role and remain a member of the Board of Directo...
Brian Stuglik to Retire from CEO Role; Continue to Serve on Company’s Board of Directors Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that Dan Paterson, P...
News, Short Squeeze, Breakout and More Instantly...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that in connection with the 2024 Russell U.S. Indexes annual reconstitution, the company will be added to the Russell 3000 ® and Russell Microcap ...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...